Akums Secures Patent for Dual-Action Morning Sickness Pill, Revolutionising Maternal Care
In a breakthrough that could transform drug delivery in maternal healthcare, Akums Drugs & Pharmaceuticals Ltd.—India’s leading pharmaceutical contract development and manufacturing organisation (CDMO)—has secured a patent for its novel extended-release formulation of Doxylamine and Pyridoxine, developed specifically to treat Nausea and Vomiting in Pregnancy (NVP).
This innovation leverages Akums’ proprietary ‘tablet-in-tablet’ technology to deliver dual-action relief—both rapid and sustained—in a single dose.
NVP, often called morning sickness, affects up to 80% of pregnant women, with around 20% continuing to experience symptoms beyond the first trimester. This condition can severely affect nutrition, mental well-being, and quality of life. Addressing this widespread but often under-treated issue, Akums has introduced a solution that combines clinical precision with patient-friendly delivery.
At the heart of the formulation is Akums’ tablet-in-tablet mechanism, which houses two distinct drug layers:
The outer layer provides immediate relief,
The inner core releases medication gradually over time.
This structure ensures reduced dosing frequency and significantly improves patient compliance—a critical factor during pregnancy, where safety and simplicity are key.
“Real innovation starts with understanding everyday challenges. This formulation for managing nausea and vomiting during pregnancy underscores our commitment to women’s health. We’re proud to help make life easier for expectant mothers,” said Sanjeev Jain, Managing Director, Akums Drugs & Pharmaceuticals Ltd.
The formulation has undergone a rigorous bioequivalence study and received approval from the Drug Controller General of India (DCGI). While specific clinical trial figures remain undisclosed due to regulatory norms, the positive outcomes validate the formulation’s safety and efficacy.
This patented product opens a new treatment avenue for stakeholders in maternal healthcare—ranging from hospitals and OB-GYN specialists to public health program implementers—proving that advanced drug delivery can drive innovation in essential care areas, far beyond chronic disease domains.
Beyond addressing a widespread maternal health issue, the development also strengthens India’s position in global pharmaceutical innovation, particularly in high-value CDMO services. With more than 4,100 commercialised formulations, 220+ innovative products in development, and a team of over 16,000 including 400+ scientists, Akums continues to set benchmarks in therapeutic R&D and scalable healthcare solutions.
This patent milestone highlights the company’s long-term focus on women’s health, reaffirming its role as a key contributor to India’s healthcare transformation.
